Literature DB >> 12393640

Rare RHCE phenotypes in black individuals of Afro-Caribbean origin: identification and transfusion safety.

France Noizat-Pirenne1, Ketty Lee, Pierre-Yves Le Pennec, Philippe Simon, Philippe Kazup, Dora Bachir, Anne-Marie Rouzaud, Michele Roussel, Geneviève Juszczak, Cècile Ménanteau, Philippe Rouger, Rami Kotb, Jean-Pierre Cartron, Hélène Ansart-Pirenne.   

Abstract

The molecular backgrounds of variants encountered in Afro-Caribbean black individuals and associated with the production of clinically significant antibodies against high-incidence antigens (anti-RH18, anti-RH34) and against Rhe epitopes were determined. We showed that RH:-18 phenotypes are produced by 3 distinct RHCE alleles: ceEK carrying 48G>C (exon 1), 712A>G, 787A>G, 800T>A (exon 5); ceBI carrying 48G>C (exon 1), 712A>G (exon 5), 818C>T (exon 6), 1132C>G (exon 8); and the already known ceAR allele carrying 48G>C (exon 1), 712A>G, 733C>G, 787A>G, 800T>A (exon 5), and 916A>G (exon 6). The RH:-34 phenotype is produced by the (C)ce(s) haplotype described previously and composed of a hybrid D-CE(3-8)-D gene with 4 extra mutations next to a ce(s) allele (733C>G; exon 5) with an extra mutation in exon 7 (1006G>T). Partial Rhe with risk of immunization against lacking epitopes can be produced by the new ce(s) allele carrying an extra mutation in exon 3 (340C>T) and by the ceMO allele described previously. A population of sickle cell disease patients was screened to estimate the incidence of these rare alleles, with the conclusion that a procedure is required to detect the associated phenotypes in black donors to ensure transfusion safety for patients. We also described a new variant [ce(s)(748)] and variants carrying different altered alleles in nonimmunized patients and for whom the risk of immunization is discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12393640     DOI: 10.1182/blood-2002-01-0229

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  31 in total

Review 1.  Molecular genetics and clinical applications for RH.

Authors:  Willy A Flegel
Journal:  Transfus Apher Sci       Date:  2011-01-28       Impact factor: 1.764

2.  RH genotyping in a sickle cell disease patient contributing to hematopoietic stem cell transplantation donor selection and management.

Authors:  Ross M Fasano; Alessandro Monaco; Emily Riehm Meier; Philippe Pary; A Hallie Lee-Stroka; John Otridge; Harvey G Klein; Francesco M Marincola; Naynesh R Kamani; Naomi L C Luban; David Stroncek; Willy A Flegel
Journal:  Blood       Date:  2010-07-19       Impact factor: 22.113

3.  Insights into RHCE Molecular Analysis in Samples with Partial D Variants: the Experience of Western France.

Authors:  Yann Fichou; Cédric Le Maréchal; Virginie Scotet; Déborah Jamet; Claude Férec
Journal:  Transfus Med Hemother       Date:  2015-07-23       Impact factor: 3.747

4.  Transfusion considerations concerning patients with anti-hrB and confounding co-morbid conditions: pregnancy and coagulopathy.

Authors:  Natasha M Savage; Wadicar F Nugent; Lawrence D Devoe; Roni J Bollag; Lloyd O Cook
Journal:  Blood Transfus       Date:  2010-12-27       Impact factor: 3.443

5.  The low-prevalence Rh antigen STEM (RH49) is encoded by two different RHCE*ce818T alleles that are often in cis to RHD*DOL.

Authors:  Marion E Reid; Christine Halter Hipsky; Kim Hue-Roye; Gail Coghlan; Coral Olsen; Christine Lomas-Francis
Journal:  Transfusion       Date:  2012-06-28       Impact factor: 3.157

6.  Variant RH alleles and Rh immunisation in patients with sickle cell disease.

Authors:  Emilia Sippert; Claudia R Fujita; Debora Machado; Glaucia Guelsin; Ane C Gaspardi; Jordão Pellegrino; Simone Gilli; Sara S T O Saad; Lilian Castilho
Journal:  Blood Transfus       Date:  2014-06-19       Impact factor: 3.443

7.  The JAL antigen (RH48) is the result of a change in RHCE that encodes Arg114Trp.

Authors:  Connie M Westhoff; Sunitha Vege; Dwane Wylie; Pam Nickle; Christine Lomas-Francis; Kim Hue-Roye; Marion E Reid
Journal:  Transfusion       Date:  2008-12-23       Impact factor: 3.157

Review 8.  How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions.

Authors:  France Pirenne; Karina Yazdanbakhsh
Journal:  Blood       Date:  2018-05-03       Impact factor: 22.113

9.  Alloanti-c in a c-positive, JAL-positive patient.

Authors:  J Ong; P S Walker; E Schmulbach; J R Storry; S Vege; C Westhoff; C Lomas-Francis; M E Reid
Journal:  Vox Sang       Date:  2008-12-05       Impact factor: 2.144

Review 10.  Genotyping in Sickle Cell Disease Patients: The French Strategy.

Authors:  Aline Floch; Christophe Tournamille; Btissam Chami; France Pirenne
Journal:  Transfus Med Hemother       Date:  2018-07-06       Impact factor: 3.747

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.